Interim report 1 January - 31 MarchSteadily increasing interest and growing acceptance for the Episurf technology: "Episurf Medical's
implants have been used in 86 surgeries in humans […] During the first half of the second quarter,
another 7 surgeries were performed, resulting in a cumulative total of 93 […] During 2015, when the commercialisation of Episurf
Medical's technology started, an average of 1.6 damage marking requests were submitted to Episurf Medical per
week. During 2016, Episurf Medical has experienced a significant increase in the number of requests. On average,
Episurf Medical received 2.6 requests per week during the first quarter. During the first 6 weeks of Q2 2016, the
equivalent figure amounted to 4.7 requests per week. This corresponds to a significant growth compared to 2015
and Episurf Medical is of the opinion that this growth will continue."This information was published, 2016-05-17 08:30 CEST --
First quarter 2016 for the Group compared to 2015
» Group net sales increased by 81% to SEK 411,834 (227,011).
» Other operating income amounted to SEK 565,286 (1,456,375).
» Income after financial items amounted to SEK –11,696,747 (–7,533,225).
» Earnings per share (weighted average) amounted to SEK –0.73 (–0.95).
» Equity per share amounted to SEK 6.16 (3.94).
» Equity ratio amounted to 94.1% (86.4).
Significant events during the first quarter
» Episurf Medical receives CE mark for its fifth product, Epioscopy® Damage Assessment Tool.
» Episurf Medical has been granted additional US patent.
» Episurf Medical launches German website and increases marketing efforts in the region.
» Episurf Medical announces that 100 account milestone has been reached.
» The scientific abstract “On the attachment of cartilage to HA: Signs of “chondrointegration” Studies on the Episealer® mini-prosthesis in the sheep knee,” has been accepted as a poster presentation at the European Society of Sport Traumatology, Knee Surgery and Arthroscopy meeting to be held in Barcelona.
Significant events after the first quarter
» Episurf Medical a nounces the appointment of its new European Marketing Director, Dan Griffiths. Dan joined the company on 25 April 2016.
» Episurf Medical receives reimbursement by private health care providers in the UK and Netherlands and further government reimbursement in Belgium.
» Episurf Medical has received the recommendation from Experien Group to follow a FDA
pre-submission and 510(K) regulatory pathway for a US market entry.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
rosemary@episurf.com
The complete Year End Report is attached to this press release and is available on the company's website.
The information in this Interim Report is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
|